Provectus appoints Pershing as CEO and Rodrigues as President effective April 16

PROVECTUS BIOPHARMACEUTICALS, INC.

Ed Pershing appointed CEO effective April 16; will continue as Board Chairman; salary $240,000/year.
Dominic Rodrigues appointed President effective April 16; will continue as Vice Chairman; salary $240,000/year.
Both executives have employment agreements with change-in-control severance provisions.
Rodrigues' prior independent contractor agreement (March 2024) terminated; he had served as chief operating consultant.
Press release outlines 2024 focus: pancreatic cancer clinical program, capital raising at fair valuation, and enhanced investor outreach.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dominic Rodrigues

President

PVCT · PROVECTUS BIOPHARMACEUTICALS, INC.

Effective: 2024-04-16
Filed: April 16, 2024, 7:59 PM ET

appointed Dominic Rodrigues as the Company’s President effective April 16, 2024.

Appointed

Ed Pershing

Chief Executive Officer

PVCT · PROVECTUS BIOPHARMACEUTICALS, INC.

Effective: 2024-04-16
Filed: April 16, 2024, 7:59 PM ET

appointed Ed Pershing as the Company’s Chief Executive Officer effective April 16, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dominic Rodrigues was appointed as President at PROVECTUS BIOPHARMACEUTICALS, INC..

Action: appointed
Role: President

Exact text from the filing

appointed Dominic Rodrigues as the Company’s President effective April 16, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ed Pershing was appointed as Chief Executive Officer at PROVECTUS BIOPHARMACEUTICALS, INC..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

appointed Ed Pershing as the Company’s Chief Executive Officer effective April 16, 2024.

View on SEC.gov

PROVECTUS BIOPHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-014848

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.